Mather Group
JANX icon

Mather Group’s Janux Therapeutics JANX Stock Holding History

Mather Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.59K Buy
+150
New +$2.52K ﹤0.01% 1982

Other funds holding JANX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
WTG
West Tower Group Richmond, Virginia $27M AUM 33.41% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Mather Group's JANX Position: Q3 2026 in Review

Mather Group opened a new position in Janux Therapeutics (JANX) in Q3 2026: 150 shares worth $2.59K. The stake represents ﹤0.01% of the portfolio and ranks #1982 among its holdings.

10 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • Mather Group held 150 shares of Janux Therapeutics worth $2.59K as of Q3 2026.
  • Janux Therapeutics was a new Mather Group position in Q3 2026.
  • Janux Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1982 holding.
  • 10 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.